Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Paula I. González-Ericsson"'
Autor:
Carlos L. Arteaga, Alan Auerbach, Richard Bryce, Alshad S. Lalani, Richard E. Cutler, Francesca Avogadri-Connors, Justin M. Balko, Melinda Sanders, Paula I. González Ericsson, Sarah Croessmann, Mellissa J. Nixon, Luigi Formisano, Angel Guerrero-Zotano, Luis J. Schwarz, Dhivya R. Sudhan
Purpose:The phase III ExteNET trial showed improved invasive disease-free survival in patients with HER2+ breast cancer treated with neratinib versus placebo after trastuzumab-based adjuvant therapy. The benefit from neratinib appeared to be greater
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ccdef9da4b82af81bb809312ab12ea87
https://doi.org/10.1158/1078-0432.c.6529268.v1
https://doi.org/10.1158/1078-0432.c.6529268.v1
Autor:
Carlos L. Arteaga, Alan Auerbach, Richard Bryce, Alshad S. Lalani, Richard E. Cutler, Francesca Avogadri-Connors, Justin M. Balko, Melinda Sanders, Paula I. González Ericsson, Sarah Croessmann, Mellissa J. Nixon, Luigi Formisano, Angel Guerrero-Zotano, Luis J. Schwarz, Dhivya R. Sudhan
Supplementary figure files
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c7717b0f2dff6e0436730482ee3aeda
https://doi.org/10.1158/1078-0432.22476023
https://doi.org/10.1158/1078-0432.22476023
Autor:
Kyung-min Lee, Chang-Ching Lin, Alberto Servetto, Joonbeom Bae, Vishal Kandagatla, Dan Ye, GunMin Kim, Dhivya R. Sudhan, Saurabh Mendiratta, Paula I. González Ericsson, Justin M. Balko, Jeon Lee, Spencer Barnes, Venkat S. Malladi, Siamak Tabrizi, Sangeetha M. Reddy, Seoyun Yum, Ching-Wei Chang, Katherine E. Hutchinson, Susan E. Yost, Yuan Yuan, Zhijian J. Chen, Yang-Xin Fu, Ariella B. Hanker, Carlos L. Arteaga
Publikováno v:
Cancer Immunol Res
The MYC oncogene is frequently amplified in triple-negative breast cancer (TNBC). Here, we show that MYC suppression induces immune-related hallmark gene set expression and tumor-infiltrating T cells in MYC-hyperactivated TNBCs. Mechanistically, MYC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1ea3a1de42e79b92f3ce9a7308ade6f
https://europepmc.org/articles/PMC9250627/
https://europepmc.org/articles/PMC9250627/
Autor:
Fabiana Napolitano, Dhivya R. Sudhan, Yunguan Wang, Paula I. González-Ericsson, Luigi Formisano, Kyung-Min Lee, Chang-Ching Lin, María Rosario Chica-Parrado, Hongli Ma, Nathaniel Evans, Alberto Servetto, Saurabh Mendiratta, Spencer Barnes, Yisheng V. Fang, Justin M. Balko, Gordon B. Mills, Marilyne Labrie, Ariella B. Hanker, Carlos L. Arteaga
Publikováno v:
Cancer Research. 83:3445-3445
We investigated the tumor microenvironment (TME) in estrogen receptor positive (ER+) primary breast cancers from stage I-III patients treated with estrogen deprivation (ED, induced with letrozole) for 10-21 days. We used primary breast cancer biopsie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a366a23d577950ce753acc7a0a5bae2d
https://doi.org/10.1158/1538-7445.am2023-3445
https://doi.org/10.1158/1538-7445.am2023-3445
Autor:
Brian D. Lehmann, Antonio Colaprico, Tiago C. Silva, Jianjiao Chen, Hanbing An, Yuguang Ban, Hanchen Huang, Lily Wang, Jamaal L. James, Justin M. Balko, Paula I. Gonzalez-Ericsson, Melinda E. Sanders, Bing Zhang, Jennifer A. Pietenpol, X. Steven Chen
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-18 (2021)
Triple negative breast cancer can be divided into additional subtypes. Here, using omics analyses, the authors show that in the mesenchymal subtype expression of MHC-1 is repressed and that this can be restored by using drugs that target subunits of
Externí odkaz:
https://doaj.org/article/0cee2f33898a4f86bcaa6cb1a2d39df1
Autor:
Na Luo, Mellissa J. Nixon, Paula I. Gonzalez-Ericsson, Violeta Sanchez, Susan R. Opalenik, Huili Li, Cynthia A. Zahnow, Michael L. Nickels, Fei Liu, Mohammed N. Tantawy, Melinda E. Sanders, H. Charles Manning, Justin M. Balko
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-11 (2018)
Immunotherapy often fails as a single option treatment in cancer. Here, the authors show that targeting of DNA methyltransferases, such as DNMT1, can potentiate anti-tumor immunity and response to checkpoint inhibition by increasing MHC gene expressi
Externí odkaz:
https://doaj.org/article/ffb91a393be74576a78dffc6f8e78041
Autor:
Na Luo, Luigi Formisano, Paula I. Gonzalez-Ericsson, Violeta Sanchez, Phillip T. Dean, Susan R. Opalenik, Melinda E. Sanders, Rebecca S. Cook, Carlos L. Arteaga, Douglas B. Johnson, Justin M. Balko
Publikováno v:
OncoImmunology, Vol 7, Iss 6 (2018)
Immunotherapies targeting programmed cell death protein 1 (PD-1) or its ligand, programmed cell death ligand 1 (PD-L1), dramatically improve the survival of melanoma patients. However, only ∼40% of treated patients demonstrate a clinical response t
Externí odkaz:
https://doaj.org/article/8ef06b5596bd49be804fbed3d49e864b